nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.08.2012

What Do We Know and We Do Not Know About Cardiovascular Autonomic Neuropathy in Diabetes

verfasst von: Rodica Pop-Busui

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Cardiovascular autonomic neuropathy (CAN) in diabetes is generally overlooked in practice, although awareness of its serious consequences is emerging. Challenges in understanding the complex, dynamic changes in the modulation of the sympathetic/parasympathetic systems’ tone and their interactions with physiologic mechanisms regulating the control of heart rate, blood pressure, and other cardiovascular functions in the presence of acute hyper-or-hypoglycemic stress, other stressors or medication, and challenges with sensitive evaluations have contributed to lower CAN visibility compared with other diabetes complications. Yet, CAN is a significant cause of morbidity and mortality, due to a high-risk of cardiac arrhythmias, silent myocardial ischemia and sudden death. While striving for aggressive risk factor control in diabetes practice seemed intuitive, recent reports of major clinical trials undermine established thinking concerning glycemic control and cardiovascular risk. This review covers current understanding and gaps in that understanding of the clinical implications of CAN and prevention and treatment of CAN.

DCCT. (1998). The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia, 41, 416–423.CrossRef

Pop-Busui, R. (2010). Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care, 33, 434–441.PubMedCrossRef

Pop-Busui, R., Low, P. A., Waberski, B. H., Martin, C. L., Albers, J. W., Feldman, E. L., Sommer, C., Cleary, P. A., Lachin, J. M., & Herman, W. H. (2009). Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation, 119, 2886–2893.PubMedCrossRef

Spallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop-Busui, R., Stevens, M., Kempler, P., Hilsted, J., Tesfaye, S., et al. (2012). Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metabolism Research and Reviews (in press).

Kempler, P., Tesfaye, S., Chaturvedi, N., Stevens, L. K., Webb, D. J., Eaton, S., Kerenyi, Z., Tamas, G., Ward, J. D., & Fuller, J. H. (2002). Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabetic Medicine, 19, 900–909.PubMedCrossRef

Low, P. A., Benrud-Larson, L. M., Sletten, D. M., Opfer-Gehrking, T. L., Weigand, S. D., O’Brien, P. C., Suarez, G. A., & Dyck, P. J. (2004). Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care, 27, 2942–2947.PubMedCrossRef

Kennedy, W. R., Navarro, X., & Sutherland, D. E. (1995). Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology, 45, 773–780.PubMedCrossRef

Singh, J. P., Larson, M. G., O’Donnell, C. J., Wilson, P. F., Tsuji, H., Lloyd-Jones, D. M., & Levy, D. (2000). Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). The American Journal of Cardiology, 86, 309–312.PubMedCrossRef

Wu, J. S., Yang, Y. C., Lin, T. S., Huang, Y. H., Chen, J. J., Lu, F. H., Wu, C. H., & Chang, C. J. (2007). Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. Journal of Clinical Endocrinology and Metabolism, 92, 3885–3889.PubMedCrossRef

10.

Navarro, X., Kennedy, W. R., & Sutherland, D. E. (1991). Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia, 34(Suppl 1), S108–S112.PubMedCrossRef

11.

O’Brien, I. A., McFadden, J. P., & Corrall, R. J. (1991). The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Quarterly Journal of Medicine, 79, 495–502.PubMed

12.

Ewing, D. J., Campbell, I. W., & Clarke, B. F. (1980). Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Annals of Internal Medicine, 92, 308–311.PubMed

13.

Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003). The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care, 26, 1895–1901.PubMedCrossRef

14.

Soedamah-Muthu, S. S., Chaturvedi, N., Witte, D. R., Stevens, L. K., Porta, M., & Fuller, J. H. (2008). Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care, 31, 1360–1366.PubMedCrossRef

15.

Gerritsen, J., Dekker, J. M., TenVoorde, B. J., Kostense, P. J., Heine, R. J., Bouter, L. M., Heethaar, R. M., & Stehouwer, C. D. (2001). Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care, 24, 1793–1798.PubMedCrossRef

16.

Lykke, J. A., Tarnow, L., Parving, H. H., & Hilsted, J. (2008). A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scandinavian Journal of Clinical and Laboratory Investigation, 68, 654–659.PubMedCrossRef

17.

Ziegler, D., Zentai, C. P., Perz, S., Rathmann, W., Haastert, B., Doring, A., & Meisinger, C. (2008). Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care, 31, 556–561.PubMedCrossRef

18.

Pop-Busui, R., Evans, G. W., Gerstein, H. C., Fonseca, V., Fleg, J. L., Hoogwerf, B. J., Genuth, S., Grimm, R. H., Corson, M. A., & Prineas, R. (2010). Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care, 33, 1578–1584.PubMedCrossRef

19.

Nordin, C. (2010). The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia, 53, 1552–1561.PubMedCrossRef

20.

Landstedt-Hallin, L., Englund, A., Adamson, U., & Lins, P. E. (1999). Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. Journal of Internal Medicine, 246, 299–307.PubMedCrossRef

21.

Robinson, R. T., Harris, N. D., Ireland, R. H., Macdonald, I. A., & Heller, S. R. (2004). Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with type 1 diabetes. Diabetologia, 47, 312–315.PubMedCrossRef

22.

DCCT. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. The New England Journal of Medicine, 329, 977–986.CrossRef

23.

UKPDS. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352, 837–853.CrossRef

24.

Cryer, P. E. (2001). Hypoglycemia-associated autonomic failure in diabetes. American Journal of Physiology, Endocrinology and Metabolism, 281, E1115–E1121.

25.

Adler, G. K., Bonyhay, I., Failing, H., Waring, E., Dotson, S., & Freeman, R. (2009). Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes, 58, 360–366.PubMedCrossRef

26.

Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2003). Diabetic autonomic neuropathy. Diabetes Care, 26, 1553–1579.PubMedCrossRef

27.

Young, L. H., Wackers, F. J., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009). Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. Journal of the American Medical Association, 301, 1547–1555.PubMedCrossRef

28.

Hage, F. G., & Iskandrian, A. E. (2011). Cardiovascular imaging in diabetes mellitus. Journal of Nuclear Cardiology, 18, 959–965.PubMedCrossRef

29.

Vinik, A. I., & Ziegler, D. (2007). Diabetic cardiovascular autonomic neuropathy. Circulation, 115, 387–397.PubMedCrossRef

30.

Axelrod, S., Lishner, M., Oz, O., Bernheim, J., & Ravid, M. (1987). Spectral analysis of fluctuations in heart rate: an objective evaluation of autonomic nervous control in chronic renal failure. Nephron, 45, 202–206.PubMedCrossRef

31.

Givertz, M. M., Sawyer, D. B., & Colucci, W. S. (2001). Antioxidants and myocardial contractility: illuminating the "Dark Side" of beta-adrenergic receptor activation? Circulation, 103, 782–783.PubMedCrossRef

32.

Iwai-Kanai, E., Hasegawa, K., Araki, M., Kakita, T., Morimoto, T., & Sasayama, S. (1999). Alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation, 100, 305–311.PubMedCrossRef

33.

Paulson, D. J., & Light, K. E. (1981). Elevation of serum and ventricular norepinephrine content in the diabetic rat. Research Communications in Chemical Pathology and Pharmacology, 33, 559–562.PubMed

34.

Drake-Holland, A. J., Van der Vusse, G. J., Roemen, T. H., Hynd, J. W., Mansaray, M., Wright, Z. M., & Noble, M. I. (2001). Chronic catecholamine depletion switches myocardium from carbohydrate to lipid utilisation. Cardiovascular Drugs and Therapy, 15, 111–117.PubMedCrossRef

35.

Schrauwen, P., Hoeks, J., & Hesselink, M. K. (2006). Putative function and physiological relevance of the mitochondrial uncoupling protein-3: involvement in fatty acid metabolism? Progress in Lipid Research, 45, 17–41.PubMedCrossRef

36.

Pop-Busui, R., Kirkwood, I., Schmid, H., Marinescu, V., Schroeder, J., Larkin, D., Yamada, E., Raffel, D. M., & Stevens, M. J. (2004). Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. Journal of the American College of Cardiology, 44, 2368–2374.PubMedCrossRef

37.

An, D., & Rodrigues, B. (2006). Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. American Journal of Physiology-Heart and Circulatory Physiology, 291, H1489–H1506.PubMedCrossRef

38.

Goodwin, G. W., Ahmad, F., Doenst, T., & Taegtmeyer, H. (1998). Energy provision from glycogen, glucose, and fatty acids on adrenergic stimulation of isolated working rat hearts. American Journal of Physiology, 274, H1239–H1247.PubMed

39.

Brown, M., Marshall, D. R., Sobel, B. E., & Bergmann, S. R. (1987). Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation, 76, 687–696.PubMedCrossRef

40.

Collins-Nakai, R. L., Noseworthy, D., & Lopaschuk, G. D. (1994). Epinephrine increases ATP production in hearts by preferentially increasing glucose metabolism. American Journal of Physiology, 267, H1862–H1871.PubMed

41.

Herrero, P., Peterson, L. R., McGill, J. B., Matthew, S., Lesniak, D., Dence, C., & Gropler, R. J. (2006). Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. Journal of the American College of Cardiology, 47, 598–604.PubMedCrossRef

42.

Feuvray, D., & Lopaschuk, G. D. (1997). Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovascular Research, 34, 113–120.PubMedCrossRef

43.

Hirabara, S. M., Silveira, L. R., Alberici, L. C., Leandro, C. V., Lambertucci, R. H., Polimeno, G. C., Cury Boaventura, M. F., Procopio, J., Vercesi, A. E., & Curi, R. (2006). Acute effect of fatty acids on metabolism and mitochondrial coupling in skeletal muscle. Biochimica et Biophysica Acta, 1757, 57–66.PubMedCrossRef

44.

Chatham, J. C., & McNeill, J. H. (Eds.). (1996). The heart in diabetes. Norwell, MA: Kluwer Academic Publishers.

45.

Francis, G. S. (2001). Diabetic cardiomyopathy: fact or fiction? Heart, 85, 247–248.PubMedCrossRef

46.

Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B., & Anversa, P. (2000). Myocardial cell death in human diabetes. Circulation Research, 87, 1123–1132.PubMedCrossRef

47.

Packer, M., O’Connor, C. M., Ghali, J. K., Pressler, M. L., Carson, P. E., Belkin, R. N., Miller, A. B., Neuberg, G. W., Frid, D., Wertheimer, J. H., et al. (1996). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. The New England Journal of Medicine, 335, 1107–1114.PubMedCrossRef

48.

Buxton, D. B., Schwaiger, M., Nguyen, A., Phelps, M. E., & Schelbert, H. R. (1988). Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux. Circulation Research, 63, 628–634.PubMedCrossRef

49.

Eichhorn, E. J., & Bristow, M. R. (1996). Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation, 94, 2285–2296.PubMedCrossRef

50.

Katz, A. M. (1986). Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation, 73, III184–III190.PubMed

51.

Mueller, H. S., & Ayres, S. M. (1977). The role of propranolol in the treatment of acute myocardial infarction. Progress in Cardiovascular Diseases, 19, 405–412.PubMedCrossRef

52.

Fang, Z. Y., Najos-Valencia, O., Leano, R., & Marwick, T. H. (2003). Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. Journal of the American College of Cardiology, 42, 446–453.PubMedCrossRef

53.

Vered, A., Battler, A., Segal, P., Liberman, D., Yerushalmi, Y., Berezin, M., & Neufeld, H. N. (1984). Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy). The American Journal of Cardiology, 54, 633–637.PubMedCrossRef

54.

Sacre, J. W., Franjic, B., Jellis, C. L., Jenkins, C., Coombes, J. S., & Marwick, T. H. (2010). Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC. Cardiovascular Imaging, 3, 1207–1215.PubMedCrossRef

55.

Fang, Z. Y., Prins, J. B., & Marwick, T. H. (2004). Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocrine Reviews, 25, 543–567.PubMedCrossRef

56.

Fang, Z. Y., Yuda, S., Anderson, V., Short, L., Case, C., & Marwick, T. H. (2003). Echocardiographic detection of early diabetic myocardial disease. Journal of the American College of Cardiology, 41, 611–617.PubMedCrossRef

57.

Rosengard-Barlund, M., Bernardi, L., Fagerudd, J., Mantysaari, M., Af Bjorkesten, C. G., Lindholm, H., Forsblom, C., Waden, J., & Groop, P. H. (2009). Early autonomic dysfunction in type 1 diabetes: a reversible disorder? Diabetologia, 52, 1164–1172.PubMedCrossRef

58.

La Rovere, M. T., Bigger, J. T., Jr., Marcus, F. I., Mortara, A., & Schwartz, P. J. (1998). Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet, 351, 478–484.PubMedCrossRef

59.

La Rovere, M. T., Pinna, G. D., Maestri, R., Robbi, E., Caporotondi, A., Guazzotti, G., Sleight, P., & Febo, O. (2009). Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. Journal of the American College of Cardiology, 53, 193–199.PubMedCrossRef

60.

Ormezzano, O., Quesada, J. L., Pierre, H., Mallion, J. M., & Baguet, J. P. (2008). Evaluation of the prognostic value of baroreflex sensitivity in hypertensive patients: the EVABAR study. Journal of Hypertension, 26, 1373–1378.PubMedCrossRef

61.

Gerson, M. C., Caldwell, J. H., Ananthasubramaniam, K., Clements, I. P., Henzlova, M. J., Amanullah, A., & Jacobson, A. F. (2011). Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circulation. Cardiovascular Imaging, 4, 87–93.PubMedCrossRef

62.

Swanson, S., Mueller, G., Raffel, D., Duvernoy, C. S., Plunkett, C., Stevens, M., & Pop-Busui, R. (2011). Left ventricle function and sympathetic innervation in type 1 diabetes. Circulation, 124, A15606.

63.

Panzer, C., Lauer, M. S., Brieke, A., Blackstone, E., & Hoogwerf, B. (2002). Association of fasting plasma glucose with heart rate recovery in healthy adults: a population-based study. Diabetes, 51, 803–807.PubMedCrossRef

64.

Ziegler, D., Zentai, C., Perz, S., Rathmann, W., Haastert, B., Meisinger, C., & Lowel, H. (2006). Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. Experimental and Clinical Endocrinology & Diabetes, 114, 153–159.CrossRef

65.

Vinik, A. I., Maser, R. E., & Ziegler, D. (2011). Autonomic imbalance: prophet of doom or scope for hope? Diabetic Medicine, 28, 643–651.PubMedCrossRef

66.

Carnethon, M. R., Prineas, R. J., Temprosa, M., Zhang, Z. M., Uwaifo, G., & Molitch, M. E. (2006). The association among autonomic nervous system function, incident diabetes, and intervention arm in the diabetes prevention program. Diabetes Care, 29, 914–919.PubMedCrossRef

67.

Chang, C. J., Yang, Y. C., Lu, F. H., Lin, T. S., Chen, J. J., Yeh, T. L., Wu, C. H., & Wu, J. S. (2010). Altered cardiac autonomic function may precede insulin resistance in metabolic syndrome. American Journal of Medicine, 123, 432–438.PubMedCrossRef

68.

Laitinen, T., Lindstrom, J., Eriksson, J., Ilanne-Parikka, P., Aunola, S., Keinanen-Kiukaanniemi, S., Tuomilehto, J., & Uusitupa, M. (2011). Cardiovascular autonomic dysfunction is associated with central obesity in persons with impaired glucose tolerance. Diabetic Medicine, 28, 699–704.PubMedCrossRef

69.

Converse, R. L., Jr., Jacobsen, T. N., Toto, R. D., Jost, C. M., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992). Sympathetic overactivity in patients with chronic renal failure. The New England Journal of Medicine, 327, 1912–1918.PubMedCrossRef

70.

Siddiqi, L., Joles, J. A., Grassi, G., & Blankestijn, P. J. (2009). Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? Journal of Hypertension, 27, 1341–1349.PubMedCrossRef

71.

Brotman, D. J., Bash, L. D., Qayyum, R., Crews, D., Whitsel, E. A., Astor, B. C., & Coresh, J. (2010). Heart rate variability predicts ESRD and CKD-related hospitalization. Journal of the American Society of Nephrology, 21, 1560–1570.PubMedCrossRef

72.

Spallone, V., Gambardella, S., Maiello, M. R., Barini, A., Frontoni, S., & Menzinger, G. (1994). Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients. Diabetes Care, 17, 578–584.PubMedCrossRef

73.

Locatelli, F., Marcelli, D., & Conte, F. (1997). Dialysis patient outcomes in Europe vs the USA. Why do Europeans live longer? Nephrology, Dialysis, Transplantation, 12, 1816–1819.PubMedCrossRef

74.

Locatelli, F., Marcelli, D., Conte, F., D’Amico, M., Del Vecchio, L., Limido, A., Malberti, F., & Spotti, D. (2001). Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. Journal of the American Society of Nephrology, 12, 2411–2417.PubMed

75.

Manjunath, G., Levey, A. S., & Sarnak, M. J. (2002). How can the cardiac death rate be reduced in dialysis patients? Seminars in Dialysis, 15, 18–20.PubMedCrossRef

76.

Hathaway, D. K., Cashion, A. K., Milstead, E. J., Winsett, R. P., Cowan, P. A., Wicks, M. N., & Gaber, A. O. (1998). Autonomic dysregulation in patients awaiting kidney transplantation. American Journal of Kidney Diseases, 32, 221–229.PubMedCrossRef

77.

Ranpuria, R., Hall, M., Chan, C. T., & Unruh, M. (2008). Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Nephrology, Dialysis, Transplantation, 23, 444–449.PubMedCrossRef

78.

Campese, V. M., Romoff, M. S., Levitan, D., Lane, K., & Massry, S. G. (1981). Mechanisms of autonomic nervous system dysfunction in uremia. Kidney International, 20, 246–253.PubMedCrossRef

79.

Brown, D. W., Giles, W. H., & Croft, J. B. (2000). Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. American Heart Journal, 140, 848–856.PubMedCrossRef

80.

Levy, D., Anderson, K. M., Savage, D. D., Balkus, S. A., Kannel, W. B., & Castelli, W. P. (1987). Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. The American Journal of Cardiology, 60, 560–565.PubMedCrossRef

81.

Nishimura, M., Hashimoto, T., Kobayashi, H., Fukuda, T., Okino, K., Yamamoto, N., Nakamura, N., Yoshikawa, T., Takahashi, H., & Ono, T. (2004). Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients. Nephrology, Dialysis, Transplantation, 19, 2532–2538.PubMedCrossRef

82.

Pacher, P., Liaudet, L., Soriano, F. G., Mabley, J. G., Szabo, E., & Szabo, C. (2002). The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes, 51, 514–521.PubMedCrossRef

83.

Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. (2008). Diabetic neuropathy: mechanisms to management. Pharmacology and Therapeutics, 120, 1–34.PubMedCrossRef

84.

Witzke, K. A., Vinik, A. I., Grant, L. M., Grant, W. P., Parson, H. K., Pittenger, G. L., & Burcus, N. (2011). Loss of RAGE defense: a cause of Charcot neuroarthropathy? Diabetes Care, 34, 1617–1621.PubMedCrossRef

85.

Wang, Y., Schmeichel, A. M., Iida, H., Schmelzer, J. D., & Low, P. A. (2006). Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury. Journal of Neurological Sciences, 247, 47–52.CrossRef

86.

Cameron, N. E., & Cotter, M. A. (2008). Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Current Drug Targets, 9, 60–67.PubMedCrossRef

87.

Kellogg, A. P., Wiggin, T., Larkin, D., Hayes, J., Stevens, M., & Pop-Busui, R. (2007). Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fibers loss in experimental diabetes. Diabetes, 56, 2997–3005.PubMedCrossRef

88.

Lieb, D. C., Parson, H. K., Mamikunian, G., & Vinik, A. I. (2012). Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Experimental Diabetes Research, 2012, 878760.PubMedCrossRef

89.

Duchen, L. W., Anjorin, A., Watkins, P. J., & Mackay, J. D. (1980). Pathology of autonomic neuropathy in diabetes mellitus. Annals of Internal Medicine, 92, 301–303.PubMed

90.

Purewal, T. S., Goss, D. E., Zanone, M. M., Edmonds, M. E., & Watkins, P. J. (1995). The splanchnic circulation and postural hypotension in diabetic autonomic neuropathy. Diabetic Medicine, 12, 513–522.PubMedCrossRef

91.

Ejskjaer, N., Arif, S., Dodds, W., Zanone, M. M., Vergani, D., Watkins, P. J., & Peakman, M. (1999). Prevalence of autoantibodies to autonomic nervous tissue structures in type 1 diabetes mellitus. Diabetic Medicine, 16, 544–549.PubMedCrossRef

92.

Rabinowe, S. L., Brown, F. M., Watts, M., & Smith, A. M. (1990). Complement-fixing antibodies to sympathetic and parasympathetic tissues in IDDM. Autonomic brake index and heart-rate variation. Diabetes Care, 13, 1084–1088.PubMedCrossRef

93.

Stroud, C. R., Heller, S. R., Ward, J. D., Hardisty, C. A., & Weetman, A. P. (1997). Analysis of antibodies against components of the autonomic nervous system in diabetes mellitus. QJM, 90, 577–585.PubMedCrossRef

94.

Granberg, V., Ejskjaer, N., Peakman, M., & Sundkvist, G. (2005). Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy. Diabetes Care, 28, 1959–1964.PubMedCrossRef

95.

Stella, P., Ellis, D., Maser, R. E., & Orchard, T. J. (2000). Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes. Incidence and predictors. Journal of Diabetes and its Complications, 14, 1–6.PubMedCrossRef

96.

Witte, D. R., Tesfaye, S., Chaturvedi, N., Eaton, S. E., Kempler, P., & Fuller, J. H. (2005). Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia, 48, 164–171.PubMedCrossRef

97.

Taskiran, M., Rasmussen, V., Rasmussen, B., Fritz-Hansen, T., Larsson, H. B., Jensen, G. B., & Hilsted, J. (2004). Left ventricular dysfunction in normotensive type 1 diabetic patients: the impact of autonomic neuropathy. Diabetic Medicine, 21, 524–530.PubMedCrossRef

98.

Pfeifer, M. A., Weinberg, C. R., Cook, D. L., Reenan, A., Halter, J. B., Ensinck, J. W., & Porte, D., Jr. (1984). Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care, 7, 447–453.PubMedCrossRef

99.

Nauman, J., Janszky, I., Vatten, L. J., & Wisloff, U. (2011). Temporal changes in resting heart rate and deaths from ischemic heart disease. Journal of the American Medical Association, 306, 2579–2587.PubMedCrossRef

100.

Furlan, R., Guzzetti, S., Crivellaro, W., Dassi, S., Tinelli, M., Baselli, G., Cerutti, S., Lombardi, F., Pagani, M., & Malliani, A. (1990). Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. Circulation, 81, 537–547.PubMedCrossRef

101.

Spallone, V., Bernardi, L., Ricordi, L., Solda, P., Maiello, M. R., Calciati, A., Gambardella, S., Fratino, P., & Menzinger, G. (1993). Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes, 42, 1745–1752.PubMedCrossRef

102.

Lurbe, E., Redon, J., Kesani, A., Pascual, J. M., Tacons, J., Alvarez, V., & Batlle, D. (2002). Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. The New England Journal of Medicine, 347, 797–805.PubMedCrossRef

103.

Schwartz, P. J., La Rovere, M. T., & Vanoli, E. (1992). Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation, 85, I77–I91.PubMed

104.

Schwartz, P. J., La Rovere, M. T., & Vanoli, E. (1996). Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology, 46, 1470.CrossRef

105.

Schwartz, P. J., La Rovere, M. T., & Vanoli, E. (1996). Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 46, 873–880.CrossRef

106.

Low, P. A., Denq, J. C., Opfer-Gehrking, T. L., Dyck, P. J., O’Brien, P. C., & Slezak, J. M. (1997). Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle & Nerve, 20, 1561–1568.CrossRef

107.

Boulton, A. J., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R., Malik, R. A., Maser, R. E., Sosenko, J. M., & Ziegler, D. (2005). Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care, 28, 956–962.PubMedCrossRef

108.

England, J. D., Gronseth, G. S., Franklin, G., Carter, G. T., Kinsella, L. J., Cohen, J. A., Asbury, A. K., Szigeti, K., Lupski, J. R., Latov, N., et al. (2009). Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle & Nerve, 39, 106–115.CrossRef

109.

Bernardi, L., Spallone, V., Stevens, M., Hilsted, J., Frontoni, S., Pop-Busui, R., Ziegler, D., Kempler, P., Freeman, R., Low, P., et al. (2012). Investigation methods for cardiac autonomic function in human research studies. Diabetes Metabolism Research and Reviews (in press).

110.

Bernardi, L., Spallone, V., Stevens, M., Hilsted, J., Frontoni, S., Pop-Busui, R., Ziegler, D., Kempler, P., Freeman, R., Low, P., et al. (1996). Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation, 93, 1043–1065.CrossRef

111.

Pichot, V., Gaspoz, J. M., Molliex, S., Antoniadis, A., Busso, T., Roche, F., Costes, F., Quintin, L., Lacour, J. R., & Barthelemy, J. C. (1999). Wavelet transform to quantify heart rate variability and to assess its instantaneous changes. Journal of Applied Physiology, 86, 1081–1091.PubMed

112.

Toledo, E., Gurevitz, O., Hod, H., Eldar, M., & Akselrod, S. (2003). Wavelet analysis of instantaneous heart rate: a study of autonomic control during thrombolysis. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 284, R1079–R1091.PubMed

113.

Raffel, D. M., & Wieland, D. M. (2001). Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nuclear Medicine and Biology, 28, 541–559.PubMedCrossRef

114.

Stevens, M. J., Raffel, D. M., Allman, K. C., Dayanikli, F., Ficaro, E., Sandford, T., Wieland, D. M., Pfeifer, M. A., & Schwaiger, M. (1998). Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation, 98, 961–968.PubMedCrossRef

115.

Stevens, M. J., Raffel, D. M., Allman, K. C., Schwaiger, M., & Wieland, D. M. (1999). Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism, 48, 92–101.PubMedCrossRef

116.

Schnell, O., Muhr, D., Weiss, M., Dresel, S., Haslbeck, M., & Standl, E. (1996). Reduced myocardial 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. Diabetes, 45, 801–805.PubMedCrossRef

117.

Caldwell, J. H., Link, J. M., Levy, W. C., Poole, J. E., & Stratton, J. R. (2008). Evidence for pre- to postsynaptic mismatch of the cardiac sympathetic nervous system in ischemic congestive heart failure. Journal of Nuclear Medicine, 49, 234–241.PubMedCrossRef

118.

Hamner, J. W., & Taylor, J. A. (2001). Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of Applied Physiology, 91, 1199–1206.PubMed

119.

DCCT/EDIC, Writing, and Group. (2003). Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Journal of the American Medical Association, 290, 2159–2167.CrossRef

120.

Azad, N., Emanuele, N. V., Abraira, C., Henderson, W. G., Colwell, J., Levin, S. R., Nuttall, F. Q., Comstock, J. P., Sawin, C. T., Silbert, C., et al. (1999). The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes and its Complications, 13, 307–313.PubMedCrossRef

121.

Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009). Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine, 360, 129–139.PubMedCrossRef

122.

Gaede, P., Vedel, P., Larsen, N., Jensen, G. V., Parving, H. H., & Pedersen, O. (2003). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal of Medicine, 348, 383–393.PubMedCrossRef

123.

Carnethon, M. R., Jacobs, D. R., Jr., Sidney, S., & Liu, K. (2003). Influence of autonomic nervous system dysfunction on the development of type 2 diabetes: the CARDIA study. Diabetes Care, 26, 3035–3041.PubMedCrossRef

124.

Carnethon, M. R., Jacobs, D. R., Jr., Sidney, S., Sternfeld, B., Gidding, S. S., Shoushtari, C., & Liu, K. (2005). A longitudinal study of physical activity and heart rate recovery: CARDIA, 1987–1993. Medicine and Science in Sports and Exercise, 37, 606–612.PubMedCrossRef

125.

Maser, R. E., & Lenhard, M. J. (2007). An overview of the effect of weight loss on cardiovascular autonomic function. Current Diabetes Reviews, 3, 204–211.PubMedCrossRef

Titel: What Do We Know and We Do Not Know About Cardiovascular Autonomic Neuropathy in Diabetes
verfasst von: Rodica Pop-Busui
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 4/2012
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-012-9367-6

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

The Clinical Relevance of the Clopidogrel–Proton Pump Inhibitor Interaction

Erratum to: Cardiovascular Disease Risk in Young People with Type 1 Diabetes

Chromatin Modifications Associated with Diabetes

The Value of Visfatin in the Prediction of Metabolic Syndrome: A Multi-Factorial Analysis